Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, Anlotinib, and Irinotecan in Second-Line SCLC
NCT05027100Unknown
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of tislelizumab and anlotinib in small cell lung cancer (SCLC). Primary endpoint: Objective Response Rate at 48 months. Status: unknown.
02
Drugs
tislelizumabanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05027100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027100.